Ionis Pharmaceuticals (IONS) – Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Ionis Pharmaceuticals (NASDAQ: IONS) recently:

  • 11/18/2026 – Ionis Pharmaceuticals had its price target lowered by Guggenheim from $80.00 to $65.00. They now have a “buy” rating on the stock.
  • 11/16/2026 – Ionis Pharmaceuticals was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
  • 11/14/2026 – Ionis Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
  • 11/10/2026 – Ionis Pharmaceuticals had its price target lowered by TD Cowen from $84.00 to $53.00. They now have a “buy” rating on the stock.
  • 11/10/2026 – Ionis Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $85.00 to $60.00. They now have an “outperform” rating on the stock.
  • 11/10/2026 – Ionis Pharmaceuticals had its price target lowered by Wells Fargo & Company from $95.00 to $80.00. They now have an “overweight” rating on the stock.
  • 11/10/2026 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by Bank of America. They now have a $63.00 price target on the stock.
  • 11/10/2026 – Ionis Pharmaceuticals had its price target lowered by The Goldman Sachs Group from $58.00 to $41.00. They now have a “neutral” rating on the stock.
  • 11/10/2026 – Ionis Pharmaceuticals had its price target lowered by Morgan Stanley from $104.00 to $75.00. They now have an “overweight” rating on the stock.
  • 11/10/2026 – Ionis Pharmaceuticals had its price target lowered by Oppenheimer from $85.00 to $70.00. They now have an “outperform” rating on the stock.
  • 11/10/2026 – Ionis Pharmaceuticals had its price target lowered by HC Wainwright from $100.00 to $70.00. They now have a “buy” rating on the stock.
  • 11/9/2026 – Ionis Pharmaceuticals had its “outperform” rating reaffirmed by Raymond James Financial. They now have a $54.00 price target on the stock.
  • 11/9/2026 – Ionis Pharmaceuticals had its price target lowered by Needham & Company LLC from $86.00 to $54.00. They now have a “buy” rating on the stock.
  • 10/22/2026 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright.
  • 10/22/2026 – Ionis Pharmaceuticals was upgraded by BMO Capital Markets from “market perform” to “outperform”. They now have a $66.00 price target on the stock, up from $54.00.
  • 10/21/2026 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by Citigroup.
  • 10/20/2026 – Ionis Pharmaceuticals was given a new $79.00 price target by Raymond James Financial.
  • 10/15/2026 – Ionis Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 10/15/2026 – Ionis Pharmaceuticals is now covered by UBS Group. They set a “buy” rating and a $88.00 price target on the stock.
  • 9/24/2026 – Ionis Pharmaceuticals had its “outperform” rating reaffirmed by Oppenheimer. They now have a $85.00 price target on the stock.
  • 9/24/2026 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $100.00 price target on the stock.
  • 9/22/2026 – Ionis Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $76.00 to $70.00. They now have an “overweight” rating on the stock.

Ionis Pharmaceuticals Stock Down 0.7%

Shares of NASDAQ:IONS opened at $27.21 on Friday. The company has a debt-to-equity ratio of 3.42, a quick ratio of 5.36 and a current ratio of 5.43. The firm has a market capitalization of $4.53 billion, a P/E ratio of -8.20 and a beta of 0.43. Ionis Pharmaceuticals, Inc. has a 52-week low of $26.55 and a 52-week high of $86.74. The stock has a 50 day moving average price of $41.31 and a 200-day moving average price of $63.46.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.57. The firm had revenue of $242.72 million for the quarter, compared to the consensus estimate of $178.17 million. Ionis Pharmaceuticals had a negative net margin of 56.98% and a negative return on equity of 120.62%. The business’s quarterly revenue was up 54.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.80) EPS. As a group, equities research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.57 EPS for the current fiscal year.

Insider Activity

In other Ionis Pharmaceuticals news, EVP Shannon L. Devers sold 1,357 shares of the stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $43.54, for a total transaction of $59,083.78. Following the transaction, the executive vice president directly owned 17,811 shares in the company, valued at $775,490.94. This represents a 7.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael R. Hayden purchased 5,000 shares of the firm’s stock in a transaction on Tuesday, November 10th. The shares were purchased at an average cost of $29.64 per share, with a total value of $148,200.00. Following the completion of the transaction, the director owned 27,000 shares of the company’s stock, valued at approximately $800,280. The trade was a 22.73% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 1.81% of the company’s stock.

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.

See Also

Receive News & Ratings for Ionis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.